Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 1, 2006, for Thermo Electron Corporation (now operating as Thermo Fisher Scientific Inc. pending merger). The company develops and manufactures analytical instruments, laboratory equipment, and specialty chemicals. The reporting period includes the impact of the adoption of SFAS No. 123R regarding share-based payment and ongoing restructuring activities.
Key Financial Metrics
| Metric | Three Months Ended July 1, 2006 | Six Months Ended July 1, 2006 |
|---|---|---|
| Revenues | $713.5 million | $1,397.8 million |
| Operating Income | $72.2 million | $140.0 million |
| Operating Margin | 10.1% | 10.0% |
| Net Income | $47.9 million | $94.8 million |
| Diluted EPS | $0.29 | $0.57 |
| Cash from Operations | N/A | $98.2 million |
| Total Debt | $639.0 million | $639.0 million |
| Cash & Equivalents | $189.7 million | $189.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 9% in the second quarter and 15% in the first six months compared to the prior year. Growth was driven by acquisitions (notably Kendro), increased demand for mass spectrometry and spectroscopy instruments, and price increases.
- Profitability: Operating income increased significantly ($72.2M vs. $53.2M in Q2 2005) due to higher demand and lower restructuring costs. However, Net Income decreased ($47.9M vs. $60.2M in Q2 2005) primarily due to the absence of a $28.9 million gain on the sale of Thoratec Corporation shares recorded in the prior year.
- Restructuring Costs: Net restructuring and other costs were $4.8 million in Q2 2006, a decrease from $13.7 million in Q2 2005. The 2005 figure included significant charges related to the Kendro acquisition inventory revaluation.
- Stock-Based Compensation: The adoption of SFAS No. 123R resulted in a pre-tax expense of $6.4 million in Q2 2006 and $11.8 million for the six-month period, reducing earnings per share by $0.03 and $0.05, respectively.
Guidance, Outlook, and Risks
- Pending Merger: The company announced a definitive agreement to merge with Fisher Scientific International Inc. in a stock-for-stock exchange valued at approximately $10.3 billion. The transaction is expected to close in the fourth quarter of 2006. Thermo will assume Fisher's debt of approximately $2.2 billion.
- Capital Allocation: The company repurchased $228.0 million of its common stock in the first six months of 2006. $72 million remains available under the current repurchase authorization.
- Restructuring Outlook: The company expects to incur an additional $5 million in charges related to a Massachusetts plant closure and approximately $1 million in other restructuring costs for the remainder of 2006.
- Key Risks:
- Integration Risk: Failure to successfully integrate Fisher Scientific could result in lost synergies, customer attrition, and diversion of management attention.
- Intellectual Property Litigation: Ongoing patent infringement lawsuit filed by Applera Corporation/MDS Inc. regarding mass spectrometer systems could result in material damages or injunctive relief.
- Goodwill Impairment: With goodwill totaling $1.99 billion, future declines in operating performance or market conditions could trigger impairment charges.
Investor Verification Checklist
- Verify the status of regulatory approvals and shareholder votes required to close the Fisher Scientific merger.
- Monitor the outcome of the patent infringement litigation with Applera Corporation/MDS Inc.
- Assess the impact of the $2.2 billion debt assumption from Fisher on the combined entity's leverage ratios.
- Review the final purchase price allocation for the EGS Gauging acquisition to confirm goodwill and intangible asset valuations.
- Track the execution of the remaining $5 million in expected restructuring charges for the Massachusetts plant closure.